News - RoActemra

Filter

Current filters:

RoActemra

Popular Filters

Roche and Chugai’s SC RoActemra improves RA long term

Roche and Chugai’s SC RoActemra improves RA long term

28-10-2013

Roche and its majority-owned Japanese subsidiary Chugai Pharmaceutical have announced that their RoActemra…

Anti-Arthritics/RheumaticsAsia-PacificChugai PharmaceuticalPharmaceuticalResearchRoActemraRoche

European prescribing attitudes for rheumatoid arthritis post-ADACTA

European prescribing attitudes for rheumatoid arthritis post-ADACTA

28-10-2013

Results from the ADACTA trial, which showed that Swiss drug major Roche’s RoActemra (tocilizumab) is…

AbbVieAnti-Arthritics/RheumaticsBiotechnologyEuropeHumiraMarkets & MarketingPfizerRoActemraRochetofactinib

Roche investing 800 million Swiss francs to expand biologics production

Roche investing 800 million Swiss francs to expand biologics production

14-10-2013

Roche said this morning it plans to invest 800 million Swiss francs ($879.2 million) within its global…

BiotechnologyEuropeFinancialGenentechKadcylaNorth AmericaPerjetaProductionRoActemraRoche

Russia's R-Pharm to develop UCB's olokizumab for rheumatoid arthritis

04-07-2013

Belgium's leading pharma company UCB (Euronext Brussels: UCB) said today (July 4) that it has granted…

Anti-Arthritics/RheumaticsLicensingolokizumabPharmaceuticalR-PharmaRoActemraRocheUCB

Roche's RoActemra shows superiority to Humira in rheumatoid arthritis

18-03-2013

Over 50% of rheumatoid arthritis patients can achieve low disease activity or remission with Swiss drug…

Anti-Arthritics/RheumaticsBiotechnologyHumiraPharmaceuticalResearchRoActemraRoche

Roche's RoActemra beats leading rival Humira in RA study; other news from EULAR

07-06-2012

Swiss drug major Roche (ROG: SIX) yesterday released new data from the ADACTA study which showed that…

Abbott LaboratoriesAnti-Arthritics/RheumaticsHumiraPharmaceuticalResearchRoActemraRoche

NICE backs Roche RoActemra, but with PAS discount

22-02-2012

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has today recommended…

Anti-Arthritics/RheumaticsEuropePharmaceuticalPricingRegulationRoActemraRoche

Mixed NICE views on Faslodex and RoActemra

14-12-2011

There was mixed news this morning from the UK’s National Institute for Health and Clinical Excellence…

Anti-Arthritics/RheumaticsAstraZenecaEuropeFaslodexOncologyPharmaceuticalPricingRegulationRoActemraRoche

UK’s NICE provisionally backs wider use of Roche’s RoActemra for rheumatoid arthritis

07-10-2011

The drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has today opened…

Anti-Arthritics/RheumaticsPharmaceuticalPricingRegulationRoActemraRoche

UK’s NICE calls for more data on Roche’s RoActemra for sJIA

11-08-2011

In a draft guidance published yesterday, UK drugs watchdog the National Institute for Health and Clinical…

Anti-Arthritics/RheumaticsEuropePharmaceuticalPricingRegulationRoActemraRoche

Roche gets EU approval for RoActemra for children with rare form of arthritis

04-08-2011

The European Commission has approved the use of Swiss drug major Roche’s (ROG: SIX) RoActemra (tocilizumab)…

Anti-Arthritics/RheumaticsEuropePharmaceuticalRegulationRoActemraRoche

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top